Skip to main content
. 2020 Aug 8;18:308. doi: 10.1186/s12967-020-02459-w

Table 2.

rhEPO protected very preterm infants against NEC

NEC Control
n/total (%)
rhEPO
n/total (%)
p-value Total
n/total (%)
Stage I 75/644 (11.6) 59/641 (9.2) 0.152 134/1285 (10.4)
Stage II 25/644 (3.9) 15/641 (2.3) 0.112 40/1285 (2.3)
Stage III 10/644 (1.6) 4/641 (0.6) 0.109 14/1285 (1.1)
Stage II and III 35/644 (5.4) 19/641 (3.0) 0.027 54/1285 (4.2)
Stage I, II and III 110/644 (17.1) 77/641 (12.0) 0.010 187/1285 (14.6)